KATHRYN TERRY, ScD
Dr. Kathryn Lynne Terry brings her expertise as a renowned reproductive epidemiologist with over 20 years of experience in studying etiology, early detection, and prevention of gynecological cancers. Kathryn Lynne Terry, ScD, is an Associate Professor of Obstetrics, Gynecology and Reproductive Biology at Brigham and Women’s Hospital and Harvard Medical School, with a secondary appointment in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health. She also serves as Associate Scientific Director of the Boston Center for Endometriosis exploring the proteomic and metabolic signatures of pelvic pain to improve diagnostic timelines and treatment strategies. During her doctoral training in cancer epidemiology. at Harvard T.H. Chan School of Public Health, she focused on the correlation of genetic variation of hormonal receptors to ovarian cancer risk Dr. Terry brings more than two decades of research experience in cancer and gynecologic diseases, with a particular focus on the role of genetic and environmental variations in risk for ovarian cancer .
Dr. Terry’s research leverages large population-based studies and international consortia to identify modifiable risk factors, uncover disease etiology, and advance early detection strategies. Her most recent work as part of the Prospective Early Detection Consortium for Ovarian Cancer” (“PREDICT”) is exploring the early detection potential of tumor-associated autoantibodies and miRNAs to complement CA 125 and imaging screening. Her work has also provided key insights into topics such as role of breastfeeding on a potentially favorable tumor-immune environment in ovarian cancer, proteomic analysis to identify the role of immune dysregulation in endometriosis to name a few. Her current NIH funded research grants examine changing contraception patterns and choices on ovarian risk and biomarker identification to advance the understanding of the underlying mechanisms that contribute to endometriosis-associated pelvic pain.
A dedicated educator and mentor, Dr. Terry has taught for over a decade, co-authored over two hundred peer-reviewed publications, and maintains a longstanding record of continuous federal and foundation funding to evaluate risk factors, genetic variants, and tissue markers in relation to ovarian cancer risk and prognosis. Through her collaborative and translational approach, she aims to bridge epidemiologic discovery with clinical application to improve outcomes for women impacted by gynecologic disease.
